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without PAC after transplantation had a significantly better 
survival rate, and BOS was less frequent with a later onset. 
PAC was the only significant parameter for the development 
of BOS stage 2 in the multivariate analysis for cytomegalovi-
rus infection, acute rejection and PAC.  Conclusions: Sinus 
surgery and daily nasal douching reduced PAC in LTx recipi-
ents. Absence of post-transplant PAC had a positive impact 
on post-transplant survival and the development of BOS. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Bilateral lung transplantation (LTx) offers true surviv-
al benefits to patients with end-stage cystic fibrosis (CF) 
lung disease if selected appropriately and timed well  [1] . 
Long-term survival of lung transplant recipients is pri-
marily limited by late allograft dysfunction and depends 
on careful post-transplant management, including the 
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 Abstract 
 Background: Lung transplantation (LTx) is a therapy for pa-
tients with cystic fibrosis (CF) end-stage lung disease. Pseu-
domonal airway colonization (PAC) is common in CF.  Objec-
tives: We investigated the influence of post-transplant sinus 
surgery and daily nasal douching on PAC after LTx and the 
influence of PAC on survival and bronchiolitis obliterans syn-
drome (BOS).  Methods: CF patients transplanted at our cen-
tre were included (November 1992 to December 2009). Clin-
ical data, including microbiological data before and after
LTx were collected. Survival and BOS following LTx were 
compared for CF recipients with and without PAC by Kaplan-
Meier statistics and Cox regression analysis.  Results: Ninety-
four CF patients were transplanted, of whom 82 (87%) under-
went sinus surgery after transplantation, and 65% of 66
patients with pre-transplant PAC had persistent PAC after 
transplantation. Upper and lower PAC is related. Patients 
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prevention and treatment of airway infections  [2] . Persis-
tent post-transplant pseudomonal airway colonization 
(PAC) could be a risk factor for bronchiolitis obliterans 
syndrome (BOS), specifically for CF patients  [3, 4] . Sinus 
surgery in combination with routine nasal care may be 
beneficial in this case  [1, 5] . Nevertheless, there is an on-
going controversy about the impact of sinus surgery com-
bined with daily nasal douching in CF lung transplant 
recipients and about post-transplant survival and the de-
velopment of BOS. 
 We systematically evaluated CF patients undergoing 
LTx at our centre and analysed the potential impact of 
routinely performed post-LTx sinus surgery combined 
with daily nasal douching on PAC after LTx. We also ex-
amined the influence of PAC on survival and the devel-
opment of BOS.
 Materials and Methods  
 Between 1992 and 2009, 94 patients with CF underwent LTx at 
the University Hospital Zurich. One patient with simultaneous 
heart-lung transplantation was not included. LTx recipients were 
followed until the end of June 2011. There was a minimal follow-
up of 18 months per patient. 
 Candidates for LTx were carefully selected following the inter-
national guidelines of the International Society for Heart and 
Lund Transplantation Pulmonary Scientific Council  [6] . The 
transplantation type was a sequential bilateral LTx, which was 
performed with extracorporeal membrane oxygenation support 
if one lung ventilation or clamping of the pulmonary artery was 
not tolerated  [1] .
 The standard protocol of immunosuppression (cyclosporine, 
azathioprine or mycophenolate mofetil and prednisolone) and in-
duction therapy (antithymocyte globuline or basiliximab) was 
followed as described by Speich et al.  [7] . Based on the sputum 
cultures, all patients underwent treatment with a combination of 
at least two antibiotics for  Pseudomonas aeruginosa (PA) for at 
least 2 weeks. Further prophylactic therapy was performed with 
cotrimoxazole, acyclovir/valacyclovir, oral itraconazole and neb-
ulized amphotericin B. Additionally, recipients with CF received 
a nebulized antibiotic therapy with colistin as prophylaxis (until 
negative PA cultures in microbiological samples of the nose as 
well as of the lung were achieved). 
 Sinus surgery was performed after recovery from transplanta-
tion [mean days after LTx 36, 95% confidence interval (CI) 24–47] 
as previously described and consisted of an endoscopic fronto-
spheno-ethmoidectomy  [5, 8] . Daily nasal douching with an iso-
tonic saline solution was started on the second day after surgery 
and continued until the end of follow-up. 
 Surveillance bronchoscopy with bronchoalveolar lavage (BAL) 
and transbronchial biopsies was performed in the first year after 
transplantation (normally every month for the first 6 months and 
when clinically indicated afterwards), along with nasal endosco-
py with aspiration of sinus secretions. The BAL of 200 ml sterile 
normal saline was normally performed in the right middle lobe 
or the lingula. The material from the BAL and the sinus aspirates 
were sent for microbiological analysis according to standard 
methods  [9] . The material was assessed semi-quantitatively;  6 10 4 
colony-forming units/ml bacteria in the sinus aspirate were con-
sidered as significant  [10] . In BAL, any bacteria growth was re-
corded as significant.
 The bacteriological results were evaluated according to the 
growth of CF-relevant pathogens in cultures, i.e. PA, Staphylococ-
cus aureus ,  Stenotrophomonas maltophilia (Steno), Achromo-
bacter (Alcaligenes) xylodoxidans  (Achromo) and  Burkholderia 
cepacia complex  (BCC). The histological criteria for acute rejec-
tion in the transbronchial biopsies were applied as described else-
where  [11] . Acute cellular rejection episodes with a grade  6 A2 
were treated with a 3-day course of methylprednisolone (at least 
5 mg/kg body weight on day 1, followed by 2 days of at least 2.5 
mg/kg body weight). 
 Patients with BAL cultures positive for the above pathogens 
received a standard antibiotic treatment according to pre-trans-
plant microbiological finding and resistance test. Patients with PA 
were treated according to antimicrobial susceptibility testing 
with at least one   -lactam or ciprofloxacin and with an amino-
glycoside (or colistin intravenously) if renal function permitted 
for at least 14 days. Persistent PAC [nasal colonization (PNC) and 
pulmonary colonization (PPC)] was defined as persistent positive 
cultures for PA (and BCC) after a trial of eradication (normally 
one course of intravenous antibiotics) in the upper and lower air-
ways. 
 The diagnostic criteria for BOS were applied as described else-
where  [2] . In the late 1990s, patients with development of BOS 1 
were treated with a macrolide (clarithromycin), and since the ear-
ly 2000s, this treatment was started even with BOS 0-p. 
 Estimated pre-LTx survival was calculated according to Liou 
et al.  [12] .
 The institutional review board of the University Hospital Zu-
rich (Kantonale Ethikkommission Zurich) approved this retro-
spective study (EK-818). 
 Statistical Analysis 
 Descriptive statistics were used, and the mean and 95% CIs 
were generally given. Two groups were formed: group A, patients 
without PA 1 year after transplantation (without PAC), and group 
B, patients with persistent PA 1 year after LTx, including 2 patients 
with BCC (with PAC). Twelve patients without sinus surgery and 
3 patients with insufficient data (all chronically infected with PA 
before transplantation) are counted as a failure of PA eradication 
(group B). The Mann-Whitney U test and Fisher’s exact test with 
a significance level set at p  ! 0.05 were used to compare between 
the two groups. Survival and BOS were analysed using Kaplan-
Meier estimates, and the log-rank test was used to compare the 
two groups for survival and BOS (all stages). Cox regression was 
applied to model the relation between occurrence of BOS (stages 
1 and 2) and cytomegalovirus (CMV) infections, cumulative rates 
of acute rejection episode in the first year (no acute rejection and 
at least one or more acute rejection episode as defined by Interna-
tional Society for Heart and Lund Transplantation grade A2)  [11] 
and PAC. IBM  SPSS  Statistics version 19 was used for the sta-
tistical analysis.
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 Results 
 Study Population 
 Ninety-four patients with CF were evaluated for LTx 
at our centre since its establishment in 1992 until De-
cember 2009. Patient demographics are displayed in  ta-
ble 1 . The majority of the patients were chronically in-
fected with PA, 2 patients were infected with BCC and 6 
patients had an  S. aureus infection alone. The estimate 
for survival without LTx was low (5-year survival of 33%). 
The 1- and 5-year survival rates after LTx were 85 and 
67%, respectively. Twenty-four patients (25.5%) had a fol-
low-up of  ! 2 years. Freedom from BOS 1 after 5 years 
was 76%.
 Twelve patients had no sinus surgery: 2 patients suf-
fered from early graft dysfunction with low post-trans-
plant forced expiratory volume in 1 s (2%), 8 patients (9%) 
died early after transplantation (early graft failure or 
multi-organ failure due to sepsis) and 2 patients (2%) were 
inoperable due to early post-transplant infection.
 Eradication of PA and Other Bacteria  
 Thirty-five percent of the 66 patients with pre-trans-
plant PAC had successful PA eradication in the sinuses 
and lungs ( table 2 ). Thirty-eight percent had persistent 
PPC and 27% had only PNC (resulting in a total of 65% 
with persistent PNC of the pre-transplant PPC). No pa-
tient had PPC alone after transplantation. 
 Overall, a total of 40% were without PAC (PPC and 
PNC) 1 year after LTx ( table 3 ). No patient without PAC 
before transplantation acquired PA after transplantation 
(over the entire observation time). 
 The 4 and 5 patients with Achromo and Steno, respec-
tively, were successfully eradicated after LTx. One of the 
2 patients with BCC had persistent colonization of the 
airways (nasal and bronchial), and the other had tran-
sient BCC in the upper and lower airways during the first 
year after LTx, which was successfully eradicated over the 
entire observation time of  1 10 years. 
 Survival and BOS 
 The 38 patients without PAC (PPC and PNC) after 
transplantation (group A) had a significantly better sur-
vival rate compared to patients with persistent PAC ( ta-
ble 4 ;  fig. 1 ). No difference was observed for BOS 0-p, but 
BOS 1 and 2 were significantly less frequent in the group 
without PAC than in the group with PAC ( fig. 2 ). The im-
pact of PAC on the development of BOS was only seen 
during the early post-transplant phase, and the mean 
time for the development of BOS was significantly earlier 
Table 1.  Baseline characteristics
Characteristics n = 94
Gender, female/male 47/47 (50/50)
Age at LTx, years 26.8 [25.1–28.5]
Microbiology before transplantation
Only S. aureus 6 (6)
PA 77 (82)
Achromo 4 (4)
Steno 5 (5)
BCC 2 (2)
Sinus surgery 82 (87)
Sinus surgery after LTx, days 26 [24–47]
Estimated 5-year survival without LTx1, % 33 [30–36]
Follow-up, years 5.7 [4.8–6.6]
1-year survival, % 85 [78–90]
5-year survival, % 67 [60–73]
Freedom of BOS 0-p at 5 years, % 47 [42–52]
Freedom of BOS 1 at 5 years, % 76 [67–82]
Freedom of BOS 2 at 5 years, % 82 [74–88]
Freedom of BOS 3 at 5 years, % 88 [79–93]
F igures in parentheses are percentages; figures in brackets are 
95% CIs.
1 According to Liou et al. [12].
Table 2.  Success and failure of PA and BCC eradication after sinus 
surgery (n = 66)1
P NC Total
no yes
PPC
No 23 (35) 18 (27) 41 (62)
Yes 0 25 (38) 25 (38)
Total 23 (35) 43 (65)
Fig ures in parentheses are percentages. F test, p < 0.0001. 
1 Thirteen patients were excluded (9 without sinus surgery and 
4 because of missing data).
Table 3.  Free from PA and BCC after LTx (n = 94)
A fter transplantation Total
no PA/BCC PA/BCC  
Before transplantation
No PA/BCC 15 (16) 0 15 (16)
PA/BCC 23 (24) 56 (60) 79 (84)
Total 38 (40) 56 (60)
Fig ures in parentheses are percentages. F test, p < 0.0001.
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in the PAC group ( table 4 ). Gender, age, pre-transplant 
prognosis without LTx, CF transmembrane conductance 
regulator genotype and episodes of acute rejections and 
CMV infections after transplantation were equally dis-
tributed in both groups. In the multivariate Cox regres-
sion analysis, persistent PAC was the only significant risk 
factor for development of BOS 2 with a hazard ration of 
3.79 (95% CI 1.10–13.11; p = 0.035), and for BOS 1, a strong 
trend was observed (hazard ratio 2.31, 95% CI 0.98–5.45; 
p = 0.055). 
 In 18 of the 28 patients with BOS 1, BAL was available 
at the time of diagnosis of BOS 1 (13 patients with PAC 
and 5 without PAC). In patients with persistent PAC, 
there was a tendency of more neutrophilic alveolitis than 
in patients without PAC (54 vs. 40%). 
Table 4.  Survival and BOS for the two groups
Group A Group B p
Patients 38 (40) 56 (60)
Gender, female/male 22/16 (58/42) 25/31 (45/55) n.s.
Age at LTx, years 26.3 [23.6–29.0] 27.1 [24.8–29.3] n.s.
CFTR genotype
Unknown 1 (3) 11 (19)
Known 37 (97) 47 (81)
dF508 homozygous 23 (62) 28 (60)
dF508 heterozygous 13 (35) 14 (30) n.s.
Without dF508 1 (3) 3 (10)
Estimate survival without LTx, % 34 [29–39] 32 [29–36] n.s.
Follow-up, years 5.7 [4.4–7.1] 5.7 [4.4–7.0] n.s.
1-year survival, % 92 [79–97] 80 [70–87] n.s.
5-year survival, % 86 [72–93] 57 [49–64] 0.007
Acute rejections (grade A2) during follow-up1
None 14 (50) 17 (44)
Once 8 (29) 15 (36) n.s.
Twice or more 6 (21) 8 (20)
CMV infection ≥1 3 (8) 4 (7) n.s.
Clarithromycin, yes/no 10/28 (27/74) 25 (45/55) n.s.
Time after LTx for BOS 0-p, years 3.7 [2.4–4.9] 3.8 [2.8–4.8] n.s.
Freedom of BOS 0-p at 5 years, % 49 [41–58] 46 [39–53] n.s.
Time after LTx for BOS 1, years 5.4 [4.1–6.8] 4.7 [3.5–5.9]
Freedom of BOS 1 at 5 years, % 85 [68–93] 69 [59–78] 0.056
Time after LTx for BOS 2, years 5.6 [4.3–6.9] 4.9 [3.7–6.1]
Freedom of BOS 2 at 5 years, % 93 [78–98] 74 [63–80] 0.025
Time after LTx for BOS 3, years 5.6 [4.3–7.0] 5.3 [4.1–6.5]
Freedom of BOS 3 at 5 years, % 93 [77–98] 84 [72–91] n.s.
F igures in parentheses are percentages; figures in brackets are 95% CIs. Group A: no PA or BCC at evaluation (15 patients) or suc-
cessful eradication of PA (nasal and bronchial) 1 year after transplantation (23 patients). Group B: chronic infection with PA at 1 year 
(including 1 patient with BCC). n.s. = Not significant; CFTR = CF transmembrane conductance regulator.
1 Twenty-six patients without transbronchial biopsies.
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 Fig. 1. Survival in patients without PA and BCC 1 year after LTx 
(without PAC) compared to infected patients with PA or BCC 
(with PAC). The log rank test was used. 
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 Discussion 
 We report three major findings: (1) the growth of  Pseu-
domonas in cultures of paranasal sinus aspirates and BAL 
after LTx was highly correlated; (2) one third of patients 
with pre-transplant PAC were successfully eradicated; 
and (3) patients with persistent PAC were at higher risk 
for the development of BOS and had a lower survival rate 
after LTx.
 Relation of PNC and PPC  
 Pseudomonal growth in cultures of sinus aspirates is 
significantly related to bacterial growth in BAL, indicat-
ing a lower risk for lung allograft infection and complica-
tions in patients with successful eradication in the sinus-
es. These findings are consistent with those of our previ-
ous study  [5] and other authors  [13–16] who recognized a 
similarity between the bacterial flora in the sinuses and 
the lower airways, suggesting cross-infection. Roby et al. 
 [13] further observed that bacteria were more likely to be 
found in the sinuses and to descend into the lower air-
ways at later stages of the CF disease. Special attention 
should be attributed to the eradication of bacteria in the 
sinuses, which requires endoscopic sinus surgery  and 
daily nasal douching with isotonic saline solution. The 
authors who did not include daily nasal care in their pro-
tocol observed no significant reduction in bacteria type 
or bacterial recolonization  [17, 18] .
 Success of Eradication  
 There are only a few studies that examine the success 
rate of  Pseudomonas eradication in post-transplant re-
cipients  [3, 5, 17, 19] . In a larger study, including 87 pa-
tients with pre-transplant sinus surgery, 82 and 87% had 
persistent PNC and PPC, respectively  [17] . In our previ-
ous study, PNC persisted in 46%  [5] . In the current study, 
persistent PNC was higher (65%) for the 66 patients with 
pre-transplant PAC. One reason for this finding could be 
the more rigid definition of PAC. Nevertheless, with our 
protocol of post-transplant sinus surgery, which was fol-
lowed by strict nasal douching, 62% of patients with pre-
transplant PAC achieved persistent PA eradication in the 
lower airways. All patients with pre-transplant Gram-
negative bacilli, other than PA and BCC (Achromo and 
Steno), were successfully eradicated after LTx. One pa-
tient with BCC had a persistent BCC infection after trans-
plantation (in the upper and lower airways), and another 
had transient BCC colonization with successful eradica-
tion over time (at the 10-year follow-up). No patient with-
out PAC before transplantation developed pseudomonal 
infection after transplantation. One reason for this find-
ing could be the strict post-transplant segregation con-
cept of our programme (prevention of cross-infection).
 PAC, Survival and BOS 
 The patients with persistent PAC (PNC and PPC) had 
a higher mortality and BOS rate compared to the Pseudo-
monas -negative patients after transplantation. This find-
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p = 0.048
p = 0.024
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Follow-up (years) Follow-up (years)a b
 Fig. 2. Freedom of BOS 1 ( a ) and BOS 2 ( b ) 
in patients without PA and BCC 1 year af-
ter LTx (without PAC) compared to infect-
ed patients with PA or BBC (with PAC). 
The log rank test was used. 
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ing is consistent to those of other groups  [3, 19–21] . Leung 
et al.  [17] , who followed a protocol of pre-transplant sinus 
surgery, observed no significant benefit to long-term sur-
vival relative to other comparable cohorts of CF patients 
with no sinus surgery. However, their protocol did not 
include daily nasal care, which is essential to achieving 
the persistent eradication of pathologic bacteria in the si-
nuses. Post-transplant PAC is associated with neutrophil-
ic airway inflammation, leading to a self-perpetuating 
cycle of airway damage and, subsequently, airway remod-
elling  [3, 22] . Neutrophilic airway inflammation plays an 
important role in chronic allograft dysfunction  [23] , and 
persistent PAC is assumed to be a risk factor for BOS. In 
our cohort, there was a tendency of more neutrophilic 
alveolitis in patients with PAC. Nevertheless, the sample 
size was too small for a valid statement. 
 The presence of pan-resistant, Gram-negative bacilli 
(other than BCC) is likely a risk factor for worse overall 
survival after LTx  [19, 21] . In our cohort of 94 patients, 
only a few patients had pan-resistant, Gram-negative ba-
cilli. All patients with  Achromobacter and  Stenotro-
phomonas  successfully eradicated these bacteria after 
transplantation, and the survival rates were even better 
than for patients with persistent PAC after transplanta-
tion. 
 We found no significant influence of acute rejection 
and CMV infections for the development of BOS, and 
persistent PAC was the only risk factor in the multivariate 
Cox regression analysis for development of BOS 2. One 
reason for this finding could be the more rigid protocol 
of post-transplant management with regular monthly 
bronchoscopic evaluation for acute rejections (and infec-
tions) and early treatment of rejection and the establish-
ment of prophylactic concepts against CMV infections 
from the beginning of our LTx program, as previously 
described  [23] . As a consequence of our therapeutic con-
cept of starting macrolide treatment when lung function 
impairment is detectable (currently in the case of BOS 
0-p), and in view of the fact that a strong trend of devel-
opment of BOS 1 was found in patients with PAC, more 
of these patients received macrolide treatment ( table 4 ). 
Nevertheless, the treatment with macrolides had no im-
pact on survival (data not shown). 
 Our study has several limitations. First, this is a ret-
rospective study, and we did not perform a randomized 
controlled trial to show the impact of sinus surgery (and 
regular nasal douching) in post-transplant CF patients. 
Nevertheless, since our establishment of the lung trans-
plant programme in 1992, we have become convinced 
that freedom from PAC must be a goal of post-trans-
plant management. To this end, we established the con-
cept of regular post-transplant surgical revision of the 
sinuses to have the best possibility of reducing the pseu-
domonal load in the sinuses. Second, we did not look for 
all confounders, which could have influenced survival 
and particularly the development of BOS. Lymphocytic 
bronchitis/bronchiolitis are recognized as classic im-
munological risk factors  [24, 25] , and other non-immu-
nological risk factors have been proposed, such as isch-
aemic reperfusion, early non-specific bronchial hyper-
responsiveness, donor and recipient age, graft ischaemic 
time, gastro-oesophageal reflux and bacterial/fungal/
non-CMV viral infections  [26] . Due to our small cohort, 
a reliable statistical analysis for these risk factors was 
difficult. 
 New concepts are appearing on the horizon. Hypo-
thetically, at least two different BOS phenotypes can be 
distinguished; apart from the neutrophilic type, which is 
responsive to azithromycin, there is another type with-
out neutrophilic inflammation  [24] . While the neutro-
philic type (probably triggered by PAC) starts early after 
transplantation (often in the first post-operative year), 
the other type is primarily diagnosed later on. This ob-
servation could be the reason we found significant devel-
opment of BOS in patients with persistent PAC in the 
early post-transplant phase but a similar survival curve 
later on.
 In conclusion, our study highlights the importance of 
early post-transplant eradication of pre-transplant PAC.
 Sinus surgery and daily nasal douching reduced bacte-
rial infection of the allograft in CF lung transplant re-
cipients and had a positive impact on post-transplant pa-
tient survival and BOS. 
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